Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach.

Mood stabilisers bipolar affective disorders depressive disorders genetics outcome studies

Journal

The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367

Informations de publication

Date de publication:
28 Feb 2022
Historique:
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 1 3 2022
Statut: aheadofprint

Résumé

Response to lithium in patients with bipolar disorder is associated with clinical and transdiagnostic genetic factors. The predictive combination of these variables might help clinicians better predict which patients will respond to lithium treatment. To use a combination of transdiagnostic genetic and clinical factors to predict lithium response in patients with bipolar disorder. This study utilised genetic and clinical data (n = 1034) collected as part of the International Consortium on Lithium Genetics (ConLi+Gen) project. Polygenic risk scores (PRS) were computed for schizophrenia and major depressive disorder, and then combined with clinical variables using a cross-validated machine-learning regression approach. Unimodal, multimodal and genetically stratified models were trained and validated using ridge, elastic net and random forest regression on 692 patients with bipolar disorder from ten study sites using leave-site-out cross-validation. All models were then tested on an independent test set of 342 patients. The best performing models were then tested in a classification framework. The best performing linear model explained 5.1% (P = 0.0001) of variance in lithium response and was composed of clinical variables, PRS variables and interaction terms between them. The best performing non-linear model used only clinical variables and explained 8.1% (P = 0.0001) of variance in lithium response. A priori genomic stratification improved non-linear model performance to 13.7% (P = 0.0001) and improved the binary classification of lithium response. This model stratified patients based on their meta-polygenic loadings for major depressive disorder and schizophrenia and was then trained using clinical data. Using PRS to first stratify patients genetically and then train machine-learning models with clinical predictors led to large improvements in lithium response prediction. When used with other PRS and biological markers in the future this approach may help inform which patients are most likely to respond to lithium treatment.

Sections du résumé

BACKGROUND BACKGROUND
Response to lithium in patients with bipolar disorder is associated with clinical and transdiagnostic genetic factors. The predictive combination of these variables might help clinicians better predict which patients will respond to lithium treatment.
AIMS OBJECTIVE
To use a combination of transdiagnostic genetic and clinical factors to predict lithium response in patients with bipolar disorder.
METHOD METHODS
This study utilised genetic and clinical data (n = 1034) collected as part of the International Consortium on Lithium Genetics (ConLi+Gen) project. Polygenic risk scores (PRS) were computed for schizophrenia and major depressive disorder, and then combined with clinical variables using a cross-validated machine-learning regression approach. Unimodal, multimodal and genetically stratified models were trained and validated using ridge, elastic net and random forest regression on 692 patients with bipolar disorder from ten study sites using leave-site-out cross-validation. All models were then tested on an independent test set of 342 patients. The best performing models were then tested in a classification framework.
RESULTS RESULTS
The best performing linear model explained 5.1% (P = 0.0001) of variance in lithium response and was composed of clinical variables, PRS variables and interaction terms between them. The best performing non-linear model used only clinical variables and explained 8.1% (P = 0.0001) of variance in lithium response. A priori genomic stratification improved non-linear model performance to 13.7% (P = 0.0001) and improved the binary classification of lithium response. This model stratified patients based on their meta-polygenic loadings for major depressive disorder and schizophrenia and was then trained using clinical data.
CONCLUSIONS CONCLUSIONS
Using PRS to first stratify patients genetically and then train machine-learning models with clinical predictors led to large improvements in lithium response prediction. When used with other PRS and biological markers in the future this approach may help inform which patients are most likely to respond to lithium treatment.

Identifiants

pubmed: 35225756
doi: 10.1192/bjp.2022.28
pii: S0007125022000289
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Subventions

Organisme : BLRD VA
ID : I01 BX003431
Pays : United States
Organisme : CSRD VA
ID : I01 CX000363
Pays : United States
Organisme : Centro de Investigación en Red de Salud Mental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centres de Recerca de Catalunya Programme/Generalitat de Catalunya, Miguel Servet II, Instituto de Salud Carlos III Intramural Research Program of the National Institute of Mental Health Intramural Research Program of the National Institute of Mental Health Investissements d'Avenir National Institute of Drug Abuse Swiss National Foundation NPU I Australian National Health and Medical Research Council INSERM (Institut National de la Santé et de la Recherche Médicale), AP-HP (Assistance Publique des Hôpitaux de Paris), Fondation FondaMental (RTRS Santé Mentale

Commentaires et corrections

Type : ErratumIn

Auteurs

Micah Cearns (M)

Discipline of Psychiatry, School of Medicine, University of Adelaide, Australia.

Azmeraw T Amare (AT)

South Australian Academic Health Science and Translation Centre, South Australian Health and Medical Research Institute (SAHMRI), Australia and Program for Quantitative Genomics, Harvard School of Public Health, USA.

Klaus Oliver Schubert (KO)

Discipline of Psychiatry, School of Medicine, University of Adelaide, Australia and Northern Adelaide Local Health Network, Mental Health Services, Australia.

Anbupalam Thalamuthu (A)

Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry, University of New South Wales, Australia.

Joseph Frank (J)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.

Fabian Streit (F)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.

Mazda Adli (M)

Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Germany.

Nirmala Akula (N)

Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA.

Kazufumi Akiyama (K)

Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University School of Medicine, Japan.

Raffaella Ardau (R)

Unit of Clinical Pharmacology, Hospital University Agency of Cagliari, Italy.

Bárbara Arias (B)

Unitat de Zoologia i Antropologia Biològica (Dpt. Biologia Evolutiva, Ecologia i Ciències Ambientals), Facultat de Biologia and Institut de Biomedicina (IBUB), University of Barcelona, CIBERSAM, Spain.

Jean-Michel Aubry (JM)

Department of Psychiatry, Mood Disorders Unit, HUG - Geneva University Hospitals, Switzerland.

Lena Backlund (L)

Department of Molecular Medicine and Surgery, Karolinska Institute, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Abesh Kumar Bhattacharjee (AK)

Department of Psychiatry, University of California San Diego, USA.

Frank Bellivier (F)

INSERM UMR-S 1144, Université Paris Diderot, Département de Psychiatrie et de Médecine Addictologique, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-F.Widal, France.

Antonio Benabarre (A)

Bipolar Disorder Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Spain.

Susanne Bengesser (S)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Austria.

Joanna M Biernacka (JM)

Department of Health Sciences Research, Mayo Clinic, USA and Department of Psychiatry and Psychology, Mayo Clinic, USA.

Armin Birner (A)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Austria.

Clara Brichant-Petitjean (C)

INSERM UMR-S 1144, Université Paris Diderot, Département de Psychiatrie et de Médecine Addictologique, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-F.Widal, France.

Pablo Cervantes (P)

The Neuromodulation Unit, McGill University Health Centre, Canada.

Hsi-Chung Chen (HC)

Department of Psychiatry & Center of Sleep Disorders, National Taiwan University Hospital, Taiwan.

Caterina Chillotti (C)

Unit of Clinical Pharmacology, Hospital University Agency of Cagliari, Italy.

Sven Cichon (S)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany; and Human Genomics Research Group, Department of Biomedicine, University Hospital Basel, Switzerland.

Cristiana Cruceanu (C)

Douglas Mental Health University Institute, McGill University, Canada.

Piotr M Czerski (PM)

Psychiatric Genetic Unit, Poznan University of Medical Sciences, Poland.

Nina Dalkner (N)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Austria.

Alexandre Dayer (A)

Department of Psychiatry, Mood Disorders Unit, HUG - Geneva University Hospitals, Switzerland.

Franziska Degenhardt (F)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany.

Maria Del Zompo (MD)

Department of Biomedical Sciences, University of Cagliari, Italy.

J Raymond DePaulo (JR)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA.

Bruno Étain (B)

INSERM UMR-S 1144, Université Paris Diderot, Département de Psychiatrie et de Médecine Addictologique, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-F.Widal, France.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Germany.

Andreas J Forstner (AJ)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany; Human Genomics Research Group, Department of Biomedicine, University Hospital Basel, Switzerland and Department of Psychiatry (UPK), University of Basel, Switzerland.

Louise Frisen (L)

Department of Molecular Medicine and Surgery, Karolinska Institute, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Mark A Frye (MA)

Department of Psychiatry and Psychology, Mayo Clinic, USA.

Janice M Fullerton (JM)

Neuroscience Research Australia, Australia and School of Medical Sciences, University of New South Wales, Australia.

Sébastien Gard (S)

Service de Psychiatrie, Hôpital Charles Perrens, France.

Julie S Garnham (JS)

Department of Psychiatry, Dalhousie University, Canada.

Fernando S Goes (FS)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA.

Maria Grigoroiu-Serbanescu (M)

Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Romania.

Paul Grof (P)

Mood Disorders Center of Ottawa, Canada.

Ryota Hashimoto (R)

Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Japan and Department of Psychiatry, Osaka University Graduate School of Medicine, Japan.

Joanna Hauser (J)

Psychiatric Genetic Unit, Poznan University of Medical Sciences, Poland.

Urs Heilbronner (U)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Germany and Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University Göttingen, Germany.

Stefan Herms (S)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany and Human Genomics Research Group, Department of Biomedicine, University Hospital Basel, Switzerland.

Per Hoffmann (P)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany and Human Genomics Research Group, Department of Biomedicine, University Hospital Basel, Switzerland.

Andrea Hofmann (A)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany.

Liping Hou (L)

Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA.

Yi-Hsiang Hsu (YH)

Program for Quantitative Genomics, Harvard School of Public Health, USA and HSL Institute for Aging Research, Harvard Medical School, USA.

Stephane Jamain (S)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, France.

Esther Jiménez (E)

Bipolar Disorder Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Spain.

Jean-Pierre Kahn (JP)

Service de Psychiatrie et Psychologie Clinique, Centre Psychothérapique de Nancy - Université de Lorraine, France.

Layla Kassem (L)

Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA.

Po-Hsiu Kuo (PH)

Department of Public Health & Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taiwan.

Tadafumi Kato (T)

Department of Psychiatry & Behavioral Science, Juntendo University, Graduate School of Medicine, Japan.

John Kelsoe (J)

Department of Psychiatry, University of California San Diego, USA.

Sarah Kittel-Schneider (S)

Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany.

Sebastian Kliwicki (S)

Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland.

Barbara König (B)

Department of Psychiatry and Psychotherapeutic Medicine, Landesklinikum Neunkirchen, Austria.

Ichiro Kusumi (I)

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Japan.

Gonzalo Laje (G)

Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA.

Mikael Landén (M)

Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the Gothenburg University, Sweden and Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.

Catharina Lavebratt (C)

Department of Molecular Medicine and Surgery, Karolinska Institute, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Marion Leboyer (M)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, AP-HP, Mondor University Hospital, DMU Impact, Fondation FondaMental, France.

Susan G Leckband (SG)

Office of Mental Health, VA San Diego Healthcare System, USA.

Mario Maj (M)

Department of Psychiatry, University of Campania 'Luigi Vanvitelli', Italy; ,for a full list of Major Depressive Disorder Working Group of the PGC Investigators, see the Supplementary Material.

Mirko Manchia (M)

Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Italy and Department of Pharmacology, Dalhousie University, Canada.

Lina Martinsson (L)

Department of Clinical Neurosciences, Karolinska Institutet, Sweden.

Michael J McCarthy (MJ)

Department of Psychiatry, University of California San Diego, USA and Department of Psychiatry, VA San Diego Healthcare System, USA.

Susan McElroy (S)

Department of Psychiatry, Lindner Center of Hope / University of Cincinnati, USA.

Francesc Colom (F)

Mental Health Research Group, IMIM-Hospital del Mar, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain.

Marina Mitjans (M)

Mental Health Research Group, IMIM-Hospital del Mar, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Spain.

Francis M Mondimore (FM)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA.

Palmiero Monteleone (P)

Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Italy.

Caroline M Nievergelt (CM)

Department of Psychiatry, University of California San Diego, USA.

Markus M Nöthen (MM)

Institute of Human Genetics, University of Bonn and Department of Genomics, Life & Brain Center, Germany.

Tomas Novák (T)

National Institute of Mental Health, Czech Republic.

Claire O'Donovan (C)

Department of Psychiatry, Dalhousie University, Canada.

Norio Ozaki (N)

Department of Psychiatry & Department of Child and Adolescent Psychiatry, Nagoya University Graduate School of Medicine, Japan.

Vincent Millischer (V)

Department of Molecular Medicine and Surgery, Karolinska Institute, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden and Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria.

Sergi Papiol (S)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Germany and Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Germany.

Andrea Pfennig (A)

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Germany.

Claudia Pisanu (C)

Department of Biomedical Sciences, University of Cagliari, Italy.

James B Potash (JB)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA.

Andreas Reif (A)

Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany.

Eva Reininghaus (E)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Austria.

Guy A Rouleau (GA)

Montreal Neurological Institute and Hospital, McGill University, Canada.

Janusz K Rybakowski (JK)

Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland.

Martin Schalling (M)

Department of Molecular Medicine and Surgery, Karolinska Institute, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Peter R Schofield (PR)

Neuroscience Research Australia, Australia and School of Medical Sciences, University of New South Wales, Australia.

Barbara W Schweizer (BW)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA.

Giovanni Severino (G)

Department of Biomedical Sciences, University of Cagliari, Italy.

Tatyana Shekhtman (T)

Department of Psychiatry, University of California San Diego, USA.

Paul D Shilling (PD)

Department of Psychiatry, University of California San Diego, USA.

Katzutaka Shimoda (K)

Department of Psychiatry, Dokkyo Medical University School of Medicine, Japan.

Christian Simhandl (C)

Bipolar Center Wiener Neustadt, Sigmund Freud University, Medical Faculty, Austria.

Claire M Slaney (CM)

Department of Psychiatry, Dalhousie University, Canada.

Alessio Squassina (A)

Department of Biomedical Sciences, University of Cagliari, Italy.

Thomas Stamm (T)

Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Germany.

Pavla Stopkova (P)

National Institute of Mental Health, Czech Republic.

Fasil Tekola-Ayele (F)

Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA.

Alfonso Tortorella (A)

Department of Psychiatry, University of Perugia, Italy.

Gustavo Turecki (G)

Douglas Mental Health University Institute, McGill University, Canada.

Julia Veeh (J)

Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany.

Eduard Vieta (E)

Bipolar Disorder Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Spain.

Stephanie H Witt (SH)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.

Gloria Roberts (G)

School of Psychiatry, University of New South Wales, Australia.

Peter P Zandi (PP)

Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, USA.

Martin Alda (M)

Department of Psychiatry, Dalhousie University, Canada.

Michael Bauer (M)

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Germany.

Francis J McMahon (FJ)

Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA.

Philip B Mitchell (PB)

School of Psychiatry, University of New South Wales, Australia.

Thomas G Schulze (TG)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany; Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Department of Health & Human Services, USA, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, USA; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Germany and Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University Göttingen, Germany.

Marcella Rietschel (M)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.

Scott R Clark (SR)

Discipline of Psychiatry, School of Medicine, University of Adelaide, Australia.

Bernhard T Baune (BT)

Department of Psychiatry and Psychotherapy, University of Münster, Germany; Department of Psychiatry, Melbourne Medical School, University of Melbourne, Australia and The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia.

Classifications MeSH